"The acquisition greatly expands the possibilities for Barrier's products and pipeline," said Al Altomari, chief executive officer of Barrier Therapeutics. "We are excited about the contributions that can be made in dermatology because of this transaction."
"The product portfolio and pipeline we have created with this acquisition further solidifies Stiefel's position as the worldwide leader in dermatology," Humphries said, "and continues to help us achieve our goal of becoming the most-respected dermatology company in the world."
The Global Headquarters of Stiefel Laboratories will remain in Coral Gables, Fla., and the Marketing and Sales headquarters will remain in Duluth, Ga.
About Barrier Therapeutics
Barrier Therapeutics is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel(R) (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion(R) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections.
Xolegel, Vusion and Solage are trademarks of Barrier Therapeutics.
About Stiefel Laboratories, Inc.
Founded in 1847, Stiefel Laboratories (a privately held company) is the
world's largest independent pharmaceutical company specializing in
dermatology. The company manufactures and ma
'/>"/>
| SOURCE Stiefel Laboratories, Inc. Copyright©2008 PR Newswire. All rights reserved |